Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite

Cited by (524)

Items 101–200 of 524

1. Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine
   Dapeng Li, David R. Martinez, Alexandra Schäfer, Haiyan Chen, Maggie Barr, Laura L. Sutherland, Esther Lee, Robert Parks, Dieter Mielke, Whitney Edwards et al. · 2022 · Nature Communications
2. Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain
   Gabriele Cerutti, Yicheng Guo, Pengfei Wang, Manoj S. Nair, Maple Wang, Yaoxing Huang, Jian Yu, Lihong Liu, Phinikoula S. Katsamba, Fabiana A. Bahna et al. · 2021 · Cell Reports
3. Dynamics of SARS-CoV-2 Spike Proteins in Cell Entry: Control Elements in the Amino-Terminal Domains
   Enya Qing, Tom Kicmal, Binod Kumar, Grant M. Hawkins, Emily C. Timm, Stanley M. Perlman, Tom Gallagher · 2021 · mBio
4. Structural mapping of antibody landscapes to human betacoronavirus spike proteins
   Sandhya Bangaru, Aleksandar Antanasijevic, Nurgun Kose, Leigh M. Sewall, Abigail M. Jackson, Naveenchandra Suryadevara, Xiaoyan Zhan, Jonathan L. Torres, Jeffrey Copps, Alba Torrents de la Peña et al. · 2022 · Science Advances
5. SARS-CoV-2 spike opening dynamics and energetics reveal the individual roles of glycans and their collective impact
   Yui Tik Pang, Atanu Acharya, Diane L. Lynch, Ànna Pavlova, James C. Gumbart · 2022 · Communications Biology
6. Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
   Wanwisa Dejnirattisai, Jiandong Huo, Daming Zhou, Jiří Zahradník, Piyada Supasa, Chang Liu, Helen M. E. Duyvesteyn, Helen Mary Ginn, Alexander J. Mentzer, Aekkachai Tuekprakhon et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
7. Potency of BNT162b2 and mRNA‐1273 vaccine‐induced neutralizing antibodies against severe acute respiratory syndrome‐CoV‐2 variants of concern: A systematic review of in vitro studies
   Maryam Noori, Seyed Aria Nejadghaderi, Shahnam Arshi, Kristin Carson‐Chahhoud, Khalil Ansarin, Ali‐Asghar Kolahi, Saeid Safiri · 2021 · Reviews in Medical Virology
8. An NTD supersite of attack
   Shee‐Mei Lok · 2021 · Cell Host & Microbe
9. Landscape of human antibody recognition of the SARS-CoV-2 receptor binding domain
   Adam K. Wheatley, Phillip Pymm, Robyn Esterbauer, Melanie H. Dietrich, Wen Shi Lee, Damien R. Drew, Hannah G. Kelly, Li‐Jin Chan, Francesca L. Mordant, Katrina A. Black et al. · 2021 · Cell Reports
10. The spike glycoprotein of SARS-CoV-2: A review of how mutations of spike glycoproteins have driven the emergence of variants with high transmissibility and immune escape
    Pedro Filho Noronha Souza, Felipe Pantoja Mesquita, Jackson L. Amaral, Patrícia G.C. Landim, Karollyny Roger Pereira Lima, Marília Braga Costa, Izabelle Rocha Farias, Mônica O. Belém, Yago O. Pinto, H. H. T. Moreira et al. · 2022 · International Journal of Biological Macromolecules
11. Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations
    Vincent Dussupt, Rajeshwer Singh Sankhala, Letzibeth Mendez-Rivera, Samantha Townsley, Fabian Schmidt, Lindsay Wieczorek, Kerri G. Lal, Gina C. Donofrio, Ursula Tran, Nathaniel D. Jackson et al. · 2021 · Nature Immunology
12. The antibody response to SARS-CoV-2 Beta underscores the antigenic distance to other variants
    Chang Liu, Da-Ming Zhou, Rungtiwa Nutalai, H. Duyvesteyn, Aekkachai Tuekprakhon, H. Ginn, W. Dejnirattisai, P. Supasa, A. Mentzer, Bei-Bei Wang et al. · 2021 · Cell Host and Microbe
13. Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies
    Gabriele Cerutti, Micah Rapp, Yicheng Guo, Fabiana A. Bahna, Jude Saber Bimela, Eswar R. Reddem, Jian Yu, Pengfei Wang, Lihong Liu, Yaoxing Huang et al. · 2021 · Structure
14. Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers
    Kanika Vanshylla, Chengcheng Fan, Marie Wunsch, Nareshkumar Poopalasingam, Matthijs Meijers, Christoph Kreer, Franziska Kleipass, Denis Ruchnewitz, Meryem Seda Ercanoglu, Henning Gruell et al. · 2021 · Cell Host & Microbe
15. An engineered ACE2 decoy neutralizes the SARS-CoV-2 Omicron variant and confers protection against infection in vivo
    Nariko Ikemura, Shunta Taminishi, Tohru Inaba, Takao Arimori, Daisuke Motooka, Kazutaka Katoh, Yuhei Kirita, Yusuke Higuchi, Songling Li, Tatsuya Suzuki et al. · 2022 · Science Translational Medicine
16. N-terminal domain mutations of the spike protein are structurally implicated in epitope recognition in emerging SARS-CoV-2 strains
    Apostolos Klinakis, Zoe Cournia, Theodoros N Rampias · 2021 · Computational and Structural Biotechnology Journal
17. Deep mutational scans of XBB.1.5 and BQ.1.1 reveal ongoing epistatic drift during SARS-CoV-2 evolution
    Ashley L. Taylor, Tyler N. Starr · 2023 · PLoS Pathogens
18. SARS-CoV-2 spike N-terminal domain modulates TMPRSS2-dependent viral entry and fusogenicity
    Bo Meng, Rawlings P. Datir, Jinwook Choi, Stephen G. Baker, Gordon Dougan, Christoph Hess, Nathalie Kingston, Paul J. Lehner, Paul Lyons, Nicholas J. Matheson et al. · 2022 · Cell Reports
19. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants
    Denise Haslwanter, M. Eugenia Dieterle, Anna Z. Wec, Cecilia M. O’Brien, Mrunal Sakharkar, Catalina Florez, Karen Tong, C. Garrett Rappazzo, Gorka Lasso, Olivia Vergnolle et al. · 2021 · mBio
20. Structural and functional insights into the spike protein mutations of emerging SARS-CoV-2 variants
    Deepali Gupta, Priyanka Sharma, Mandeep Singh, Mukesh Kumar, Abdul Samath Ethayathulla, Punit Kaur · 2021 · Cellular and Molecular Life Sciences
21. Inter-domain communication in SARS-CoV-2 spike proteins controls protease-triggered cell entry
    Enya Qing, Pengfei Li, Laura M. Cooper, Sebastian R. Schulz, Hans‐Martin Jäck, Lijun Rong, Stanley M. Perlman, Tom Gallagher · 2022 · Cell Reports
22. Rapid characterization of spike variants via mammalian cell surface display
    Kamyab Javanmardi, Chia‐Wei Chou, Cynthia I. Terrace, Ankur Annapareddy, Tamer Saad Kaoud, Qingqing Guo, Josh Lutgens, Hayley Zorkic, Andrew P. Horton, Elizabeth C. Gardner et al. · 2021 · Molecular Cell
23. Omicron (BA.1) and Sub-Variants (BA.1, BA.2 and BA.3) of SARS-CoV-2 Spike Infectivity and Pathogenicity: A Comparative Sequence and Structural-based Computational Assessment
    Kumar, Suresh, Karuppanan, Kalimuthu, Subramaniam, Gunasekaran · 2022
24. Protective neutralizing epitopes in SARS‐CoV‐2
    Hejun Liu, Ian A. Wilson · 2022 · Immunological Reviews
25. SARS-CoV-2 spike protein: structure, viral entry and variants
    Bing Chen, Michael Farzan, Hyeryun Choe · 2025 · Nature Reviews Microbiology
26. Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: a serological analysis
    Frauke Muecksch, Helen M. Wise, Kate E Templeton, Becky Batchelor, Maria Squires, Kirsty McCance, LISA M. JARVIS, Kristen Malloy, Elizabeth Furrie, Claire Richardson et al. · 2022 · The Lancet Microbe
27. Spike Protein NTD mutation G142D in SARS-CoV-2 Delta VOC lineages is associated with frequent back mutations, increased viral loads, and immune evasion
    Li Shen, Timothy Junius Triche, Jennifer Dien Bard, Jaclyn A. Biegel, Alexander Russell Judkins, Xiaowu Gai · 2021 · medRxiv
28. Integrative overview of antibodies against SARS-CoV-2 and their possible applications in COVID-19 prophylaxis and treatment
    Norma A. Valdez‐Cruz, Enrique García‐Hernández, Clara Espitia, Laura Cobos-Marín, Claudia Altamirano, Carlos G. Bando-Campos, Luis Fernando Cofas‐Vargas, Enrique Wenceslao Coronado-Aceves, Ricardo A. González-Hernández, Pablo Hernández‐Peralta et al. · 2021 · Microbial Cell Factories
29. Variants of Concern Are Overrepresented Among Postvaccination Breakthrough Infections of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Washington State
    Abbye E. McEwen, Seth Cohen, Chloe Bryson‐Cahn, Catherine Liu, Steven A. Pergam, John B. Lynch, Adrienne Schippers, Kathy Strand, Estella E. Whimbey, Nandita S Mani et al. · 2021 · Clinical Infectious Diseases
30. Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron
    I‐Ting Teng, Alexandra F. Nazzari, Misook Choe, Tracy W. B. Liu, Matheus Oliveira de Souza, Yuliya I. Petrova, Yaroslav Tsybovsky, Shuishu Wang, Baoshan Zhang, Mykhaylo V Artamonov et al. · 2022 · PLoS ONE
31. Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron
    Lidong Wang, Michelle Møhlenberg, Pengfei Wang, Hao Zhou · 2023 · Cytokine & Growth Factor Reviews
32. A neutralizing epitope on the SD1 domain of SARS-CoV-2 spike targeted following infection and vaccination
    Jeffrey Seow, Hataf Khan, Annachiara Rosa, Valeria Calvaresi, Carl Graham, Suzanne Pickering, Valerie E. Pye, Nora Cronin, Isabella Huettner, Michael H. Malim et al. · 2022 · Cell Reports
33. Domain-based mRNA vaccines encoding spike protein N-terminal and receptor binding domains confer protection against SARS-CoV-2
    Guillaume Stewart-Jones, Sayda M. Elbashir, Kai Wu, Diana Lee, Isabella Renzi, Baoling Ying, Matthew Koch, Caralyn E. Sein, Angela Choi, Bradley M. Whitener et al. · 2023 · Science Translational Medicine
34. A monoclonal antibody that neutralizes SARS-CoV-2 variants, SARS-CoV, and other sarbecoviruses
    Pengfei Wang, Ryan G. Casner, Manoj S. Nair, Jian Yu, Yicheng Guo, Maple Wang, Jasper Fuk‐Woo Chan, Gabriele Cerutti, Sho Iketani, Lihong Liu et al. · 2021 · Emerging Microbes & Infections
35. Template switching and duplications in SARS-CoV-2 genomes give rise to insertion variants that merit monitoring
    Sofya K. Garushyants, Igor B. Rogozin, Eugene V. Koonin · 2021 · Communications Biology
36. The Development of SARS-CoV-2 Variants: The Gene Makes the Disease
    Raquel Pérez-Gómez · 2021 · Journal of Developmental Biology
37. Multiple expansions of globally uncommon SARS-CoV-2 lineages in Nigeria
    Egon Anderson Ozer, Lacy M. Simons, Moses Olubusuyi Adewumi, Adeola Fowotade, Ewean Chukwuma Omoruyi, Johnson Adekunle Adeniji, Oluseyi Adebowale Olayinka, Taylor J. Dean, Janet P. Zayas, Pavan P. Bhimalli et al. · 2022 · Nature Communications
38. The ongoing evolution of variants of concern and interest of SARS-CoV-2 in Brazil revealed by convergent indels in the amino (N)-terminal domain of the spike protein
    Paola Cristina Resende, Felipe Gomes Naveca, Roberto Dias Lins, Filipe Zimmer Dezordi, Matheus Vitor Ferreira Ferraz, Emerson Gonçalves Moreira, Danilo F. Coêlho, Fernando Couto Motta, Anna Carolina Dias Paixão, Luciana Appolinario et al. · 2021 · Virus Evolution
39. Emergence of a recurrent insertion in the N-terminal domain of the SARS-CoV-2 spike glycoprotein
    Marco Gerdol, Klevia Dishnica, Alejandro Giorgetti · 2022 · Virus Research
40. Arsenal of nanobodies shows broad-spectrum neutralization against SARS-CoV-2 variants of concern in vitro and in vivo in hamster models
    Martín A. Rossotti, Henk van Faassen, Anh Tran, Joey G. Sheff, Jagdeep K. Sandhu, Diana Duque, Melissa Hewitt, Xiaoxue Wen, Jegarubee Bavananthasivam, Saina Beitari et al. · 2022 · Communications Biology
41. SARS-CoV-2 journey: from alpha variant to omicron and its sub-variants
    Dima Hattab, Mumen F. A. Amer, Zina M. Al‐Alami, Athirah Bakhtiar · 2024 · Infection
42. Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination
    William N. Voss, Michael L. Mallory, Patrick O. Byrne, Jeffrey Marchioni, Sean A. Knudson, John M. Powers, Sarah R. Leist, Bernadeta Dadonaite, Douglas R. Townsend, Jessica Kain et al. · 2024 · Cell Reports Medicine
43. Molecular Virology of SARS-CoV-2 and Related Coronaviruses
    Yu-An Kung, Kuo-Ming Lee, Huan-Jung Chiang, Sheng‐Yu Huang, Chung-Jung Wu, Shin‐Ru Shih · 2022 · Microbiology and Molecular Biology Reviews
44. Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses
    Aiste Dijokaite-Guraliuc, Raksha Das, Daming Zhou, Helen Mary Ginn, Chang Liu, Helen M. E. Duyvesteyn, Jiandong Huo, Rungtiwa Nutalai, Piyada Supasa, Muneeswaran Selvaraj et al. · 2023 · Cell Reports
45. Primary exposure to SARS-CoV-2 variants elicits convergent epitope specificities, immunoglobulin V gene usage and public B cell clones
    Noemia S. Lima, Maryam Mukhamedova, Timothy S. Johnston, Danielle A. Wagner, Amy R. Henry, Lingshu Wang, Eun Sung Yang, Yi Zhang, Kevina Birungi, Walker P. Black et al. · 2022 · Nature Communications
46. Enhanced protective immunity against SARS-CoV-2 elicited by a VSV vector expressing a chimeric spike protein
    Hongyue Li, Yuhang Zhang, Dong Li, Yong‐Qiang Deng, Hongde Xu, Chaoyue Zhao, Jiandong Liu, Dan Wen, Jianguo Zhao, Yongchun Li et al. · 2021 · Signal Transduction and Targeted Therapy
47. High-throughput identification of prefusion-stabilizing mutations in SARS-CoV-2 spike
    Timothy J.C. Tan, Zongjun Mou, Ruipeng Lei, Wenhao O. Ouyang, Meng Yuan, Ge Song, Raiees Andrabi, Ian A. Wilson, Collin Kieffer, Xinghong Dai et al. · 2023 · Nature Communications
48. Principles of SARS-CoV-2 glycosylation
    Himanshi Chawla, Elisa Fadda, Max Crispin · 2022 · Current Opinion in Structural Biology
49. A third dose of inactivated vaccine augments the potency, breadth, and duration of anamnestic responses against SARS-CoV-2
    Kang Wang, Yunlong Cao, Yunjiao Zhou, Jiajing Wu, Zijing Jia, Yaling Hu, Ayijiang Yisimayi, Wangjun Fu, Lei Wang, Pan Liu et al. · 2021 · medRxiv
50. SARS-CoV-2 spike E156G/Δ157-158 mutations contribute to increased infectivity and immune escape
    Tarun Kumar Mishra, Rishikesh Dalavi, Garima Joshi, Atul Kumar, Pankaj Pandey, Sanjeev Shukla, Ram Kumar Mishra, Ajit G. Chande · 2022 · Life Science Alliance
51. Allosteric perspective on the mutability and druggability of the SARS-CoV-2 Spike protein
    Zhen Wah Tan, Wei-Ven Tee, Firdaus Samsudin, Enrico Guarnera, Peter John Bond, Igor N. Berezovsky · 2022 · Structure
52. The fatty acid site is coupled to functional motifs in the SARS-CoV-2 spike protein and modulates spike allosteric behaviour
    A. Sofia F. Oliveira, Deborah K. Shoemark, Amaurys Ávila Ibarra, Andrew D. Davidson, Imre Berger, Christiane Schaffitzel, Adrian John Mulholland · 2021 · Computational and Structural Biotechnology Journal
53. Antibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein
    Kamyab Javanmardi, Thomas H. Segall-Shapiro, Chia‐Wei Chou, Daniel R. Boutz, Randall J. Olsen, Xuping Xie, Hongjie Xia, Pei‐Yong Shi, Charlie D. Johnson, Ankur Annapareddy et al. · 2022 · Cell Host & Microbe
54. Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants
    William R. Strohl, Zhiqiang Ku, Zhiqiang An, Stephen F. Carroll, Bruce A. Keyt, Lila M. Strohl · 2022 · BioDrugs
55. Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trial
    Spyros Chalkias, Patrick Dennis, Dena Petersen, Krishnakumar Radhakrishnan, Leroy B. Vaughan, Reem Handforth, Alexandra Rossi, Rahnuma Wahid, Darin K. Edwards, Jing Feng et al. · 2025 · The Lancet Infectious Diseases
56. The localized rise of a B.1.526 SARS-CoV-2 variant containing an E484K mutation in New York State
    Erica Lasek‐Nesselquist, Pascal Lapierre, Erasmus Schneider, Kirsten St. George, Janice D. Pata · 2021 · medRxiv
57. Coincident rapid expansion of two SARS-CoV-2 lineages with enhanced infectivity in Nigeria
    Ozer, Egon A., Simons, Lacy M., Adewumi, Olubusuyi M., Fowotade, Adeola A., Omoruyi, Ewean C., Adeniji, Johnson A., Dean, Taylor J., Zayas, Janet, Bhimalli, Pavan P., Ash, Michelle K. et al. · 2021
58. A Highly Potent SARS-CoV-2 Blocking Lectin Protein
    Recep Erdem Ahan, Alireza Hanifehnezhad, Ebru Ş. Kehribar, Tuba Çiğdem Oğuzoğlu, Katalin Földes, Cemile E. Özçelik, Nazlıcan Filazi, Sıdıka Öztop, Fahreddin Palaz, Sevgen Önder et al. · 2022 · ACS Infectious Diseases
59. A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS‐CoV‐2 infection model
    Antonia Sophia Peter, Edith A. Roth, Sebastian R. Schulz, Kirsten Fraedrich, Tobit D. Steinmetz, Dominik Damm, Manuela Hauke, Elie Richel, Sandra M. Mueller-Schmucker, Katharina Marie Habenicht et al. · 2021 · European Journal of Immunology
60. Antigenic evolution of SARS coronavirus 2
    Anna Z. Mykytyn, Ron A. M. Fouchier, Bart L. Haagmans · 2023 · Current Opinion in Virology
61. Analysis of Glycosylation and Disulfide Bonding of Wild-Type SARS-CoV-2 Spike Glycoprotein
    Shijian Zhang, Eden P. Go, Haitao Ding, Saumya Anang, John C. Kappes, Heather Desaire, Joseph Sodroski · 2021 · Journal of Virology
62. Case Series: Convalescent Plasma Therapy for Patients with COVID-19 and Primary Antibody Deficiency
    Julia Lang‐Meli, Jonas Fuchs, Philipp Mathé, Hsi-en Ho, Lisa Kern, Lena Jaki, Giuseppe Rusignuolo, Susanne Mertins, Vivien Somogyi, Christoph Neumann‐Haefelin et al. · 2021 · Journal of Clinical Immunology
63. Antibodies induced by an ancestral SARS-CoV-2 strain that cross-neutralize variants from Alpha to Omicron BA.1
    Ian W. Windsor, Pei Tong, Olivia Lavidor, Ali Sanjari Moghaddam, Lindsay G. A. McKay, Avneesh Kumar Gautam, Yuezhou Chen, Elizabeth A. MacDonald, Duck Kyun Yoo, Anthony Griffths et al. · 2022 · Science Immunology
64. Characterization of the SARS-CoV-2 B.1.621 (Mu) variant
    Peter Halfmann, Makoto Kuroda, Tammy Armbrust, James P. Theiler, Ariane Balaram, Gage K. Moreno, Molly A. Accola, Kiyoko Iwatsuki‐Horimoto, Riccardo Valdez, Emily K. Stoneman et al. · 2022 · Science Translational Medicine
65. Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability
    Wei Shi, Lingshu Wang, Tongqing Zhou, Mallika Sastry, Eun Sung Yang, Yi Zhang, Man Chen, Xuejun Chen, Misook Choe, Adrian Creanga et al. · 2022 · Structure
66. Evolutionary remodelling of N‐terminal domain loops fine‐tunes SARS‐CoV‐2 spike
    Diego M. Cantoni, Matthew J Murray, Mphatso D. Kalemera, Samuel J. Dicken, Lenka Stejskal, Georgina Brown, Spyros Lytras, Jonathon D. Coey, James Patrick McKenna, Stephen Bridgett et al. · 2022 · EMBO Reports
67. An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer
    Naveenchandra Suryadevara, Andrea R. Shiakolas, Laura A. VanBlargan, Elad Binshtein, Rita E. Chen, James Brett Case, Kevin J. Kramer, Erica Armstrong, Luke Myers, Andrew Trivette et al. · 2022 · Journal of Clinical Investigation
68. The Immune Response to SARS-CoV-2 and Variants of Concern
    Elham Torbati, Kurt L. Krause, James E. Ussher · 2021 · Viruses
69. Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking
    Lihong Liu, Ryan G. Casner, Yicheng Guo, Qian Wang, Sho Iketani, Jasper Fuk‐Woo Chan, Jian Yu, Bernadeta Dadonaite, Manoj S. Nair, Hiroshi Mohri et al. · 2023 · Immunity
70. Antibody escape and global spread of SARS-CoV-2 lineage A.27
    Tamara Kaleta, Lisa Kern, Samuel Leandro Hong, Martin Hölzer, Georg Kochs, Julius Beer, Daniel Schnepf, Martin Schwemmle, Nena Bollen, Philipp Kolb et al. · 2022 · Nature Communications
71. Targeting the Spike Receptor Binding Domain Class V Cryptic Epitope by an Antibody with Pan-Sarbecovirus Activity
    Jaime L. Jensen, Rajeshwer Singh Sankhala, Vincent Dussupt, Hongjun Bai, Agnes Hajduczki, Kerri G. Lal, William C. Chang, Elizabeth J. Martinez, Caroline E. Peterson, Emily S. Golub et al. · 2023 · Journal of Virology
72. Mapping cross-variant neutralizing sites on the SARS-CoV-2 spike protein
    Shiqi Xu, Yifan Wang, Yanxing Wang, Chao Zhang, Hong Qin, Chenjian Gu, Rong Xu, Tingfeng Wang, Yong Ping Yang, Jinkai Zang et al. · 2021 · Emerging Microbes & Infections
73. A structure-function analysis shows SARS-CoV-2 BA.2.86 balances antibody escape and ACE2 affinity
    Chang Liu, Daming Zhou, Aiste Dijokaite-Guraliuc, Piyada Supasa, Helen M. E. Duyvesteyn, Helen Mary Ginn, Muneeswaran Selvaraj, Alexander J. Mentzer, Raksha Das, Thushan I. de Silva et al. · 2024 · Cell Reports Medicine
74. Further antibody escape by Omicron BA.4 and BA.5 from vaccine and BA.1 serum
    Aekkachai Tuekprakhon, Jiandong Huo, Rungtiwa Nutalai, Aiste Dijokaite-Guraliuc, Daming Zhou, Helen Mary Ginn, Muneeswaran Selvaraj, Chang Liu, Alexander J. Mentzer, Piyada Supasa et al. · 2022 · bioRxiv (Cold Spring Harbor Laboratory)
75. Immune Evasion of SARS-CoV-2 Omicron Subvariants
    Hanzhong Ke, Matthew Chang, Wayne Anthony Marasco · 2022 · Vaccines
76. Structural Immunology of SARS ‐ CoV ‐2
    Meng Yuan, Ian A. Wilson · 2024 · Immunological Reviews
77. The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies
    Alexandra J. Spencer, Susan Jane Morris, Marta Ulaszewska, Claire Powers, Reshma Kailath, Cameron Bissett, Adam Truby, Nazia Thakur, Joseph Newman, Elizabeth R. Allen et al. · 2022 · EBioMedicine
78. A combination vaccine against SARS-CoV-2 and H1N1 influenza based on receptor binding domain trimerized by six-helix bundle fusion core
    Rui Shi, Jiawei Zeng, Ling Xu, Fengze Wang, Xiaomin Duan, Yue Wang, Zheng Wu, Dandan Yu, Qingrui Huang, Yong‐Gang Yao et al. · 2022 · EBioMedicine
79. Structure-activity relationships of B.1.617 and other SARS-CoV-2 spike variants
    Tzu‐Jing Yang, Pei‐Yu Yu, Yuan‐Chih Chang, Ning-En Chang, Yu-Xi Tsai, Kang-Hao Liang, Piotr Drączkowski, Bertina Lin, Yongsheng Wang, Yu-Chun Chien et al. · 2021 · bioRxiv (Cold Spring Harbor Laboratory)
80. Defining neutralization and allostery by antibodies against COVID-19 variants
    Nikhil Kumar Tulsian, Palur Venkata Raghuvamsi, Xinlei Qian, Yue Gu, Bhuvaneshwari D O Shunmuganathan, Firdaus Samsudin, Yee Hwa Wong, Jianqing Lin, Kiren Purushotorman, Mary Kozma et al. · 2023 · Nature Communications
81. Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale synthetic phage libraries
    Tom Z. Yuan, Pankaj Garg, Linya Wang, Jordan R. Willis, Eric Kwan, Ana G Lujan Hernandez, Emily Tuscano, Emily N. Sever, Erica Keane Rivera, Cinque S. Soto et al. · 2021 · mAbs
82. Role of spike in the pathogenic and antigenic behavior of SARS-CoV-2 BA.1 Omicron
    Da-Yuan Chen, D. Kenney, C. Chin, A. H. Tavares, Nazimuddin Khan, Hasahn L. Conway, Guanqun Liu, M. Choudhary, H. Gertje, A. O'Connell et al. · 2022 · bioRxiv
83. Combination of S1–N–Terminal and S1–C–Terminal Domain Antigens Targeting Double Receptor-Binding Domains Bolsters Protective Immunity of a Nanoparticle Vaccine against Porcine Epidemic Diarrhea Virus
    Dan Yang, Mingjun Su, Donghua Guo, Feiyu Zhao, Meijiao Wang, Jiaying Liu, Jingxuan Zhou, Yingming Sun, Xu Yang, Shanshan Qi et al. · 2024 · ACS Nano
84. Exploring the immune evasion of SARS-CoV-2 variant harboring E484K by molecular dynamics simulations
    Leyun Wu, Cheng Peng, Yanqing Yang, Yulong Shi, Liping Zhou, Zhijian Xu, Weiliang Zhu · 2021 · Briefings in Bioinformatics
85. High diversity in Delta variant across countries revealed by genome‐wide analysis of SARS‐CoV‐2 beyond the Spike protein
    Rohit Suratekar, Pritha Ghosh, Michiel J.M. Niesen, Gregory Donadio, Praveen Anand, Venky Soundararajan, AJ Venkatakrishnan · 2022 · Molecular Systems Biology
86. Research progress on vaccine efficacy against SARS-CoV-2 variants of concern
    Lianlian Bian, Jianyang Liu, Fan Gao, Qiushuang Gao, Qian He, Qunying Mao, Xing Wu, Miao Xu, Zhenglun Liang · 2022 · Human Vaccines & Immunotherapeutics
87. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern
    Mengqi Yuan, Xiangyu Chen, Yanzhi Zhu, Xiaoqing Dong, Yan Liu, Zhaohui Qian, Lilin Ye, Pinghuang Liu · 2022 · Journal of Virology
88. Probing the biophysical constraints of SARS-CoV-2 spike N-terminal domain using deep mutational scanning
    Wenhao O. Ouyang, Timothy J.C. Tan, Ruipeng Lei, Ge Song, Collin Kieffer, Raiees Andrabi, Kenneth A. Matreyek, Nicholas C. Wu · 2022 · Science Advances
89. Longitudinal single-cell analysis of SARS-CoV-2–reactive B cells uncovers persistence of early-formed, antigen-specific clones
    Lydia Scharf, Hannes Axelsson, Aikaterini Emmanouilidi, Nimitha R. Mathew, Daniel J. Sheward, Susannah Leach, Pauline Isakson, Ilya Valerevich Smirnov, Emelie Marklund, Nicolae Miron et al. · 2022 · JCI Insight
90. S glycoprotein diversity of the Omicron variant
    Rakesh Sarkar, Mahadeb Lo, Ritubrita Saha, Shanta Dutta, Mamta Chawla‐Sarkar · 2021 · medRxiv
91. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients
    Yuko Nitahara, Yu Nakagama, Natsuko Kaku, Katherine Candray, Yu Michimuko, Evariste Tshibangu-Kabamba, Akira Kaneko, Hiromasa Yamamoto, Yasumitsu Mizobata, Hiroshi Kakeya et al. · 2021 · Microbiology Spectrum
92. Rapid test to assess the escape of SARS-CoV-2 variants of concern
    Jacob T. Heggestad, Rhett J. Britton, David Kinnamon, Simone A. Wall, Daniel Y. Joh, Angus Hucknall, Lyra B. Olson, Jack G. Anderson, Anna Mazur, Cameron R. Wolfe et al. · 2021 · Science Advances
93. Dynamics of SARS-CoV-2 Alpha (B.1.1.7) variant spread: The wastewater surveillance approach
    Albert Carcereny, David García-Pedemonte, Adán Martínez-Velázquez, Josep Quer, Damir García‐Cehic, Josep Gregori, Andrés Antón, Cristina Andrés, Tomàs Pumarola, Carme Chacón-Villanueva et al. · 2022 · Environmental Research
94. 35B5 antibody potently neutralizes SARS-CoV-2 Omicron by disrupting the N-glycan switch via a conserved spike epitope
    Xiaofei Wang, Xiangyu Chen, Jiaxing Tan, Shuai Yue, Runhong Zhou, Yan Xu, Yao Lin, Yang Yang, Yan Wen Zhou, Kai Deng et al. · 2022 · Cell Host & Microbe
95. The SARS-CoV-2 Delta variant induces an antibody response largely focused on class 1 and 2 antibody epitopes
    Allison J. Greaney, Rachel T. Eguia, Tyler N. Starr, Khadija Khan, Nicholas Franko, Jennifer K. Logue, Sandra M. Lord, Cate Speake, Helen Y. Chu, Alex Sigal et al. · 2022 · PLoS Pathogens
96. An overview of methods for the structural and functional mapping of epitopes recognized by anti-SARS-CoV-2 antibodies
    Irené M. Francino-Urdaniz, Timothy A. Whitehead · 2021 · RSC Chemical Biology
97. Antibody-mediated immunity to SARS-CoV-2 spike
    John M. Errico, Lucas J. Adams, Daved H. Fremont · 2022 · Advances in immunology
98. The effects of amino acid substitution of spike protein and genomic recombination on the evolution of SARS-CoV-2
    Letian Fang, Jie Xu, Yue Zhao, Junyan Fan, Jiaying Shen, Wenbin Liu, Guangwen Cao · 2023 · Frontiers in Microbiology
99. The S2 subunit of spike encodes diverse targets for functional antibody responses to SARS-CoV-2
    Jamie Guenthoer, Meghan E. Garrett, Michelle Lilly, Delphine Depierreux, Felicitas Ruiz, Margaret Chi, Caitlin I. Stoddard, Vrasha Chohan, Zak A. Yaffe, Kevin Sung et al. · 2024 · PLoS Pathogens
100. Rapid identification of neutralizing antibodies against SARS-CoV-2 variants by mRNA display
     Shiho Tanaka, C. Anders Olson, Christopher O. Barnes, Wendy Higashide, Marcos R. Gonzalez, Justin D. Taft, Ashley Richardson, Marta Martín-Fernández, Dusan Bogunovic, Priyanthi N.P. Gnanapragasam et al. · 2022 · Cell Reports